Cellavision

"Management strikes a balanced tone — celebrating a strong Q1 with specific metrics while explicitly flagging macro volatility, trade uncertainty, and regulatory conditionality. For a healthcare/medtech company, some hedging around regulatory timelines is entirely normal; however, the explicit acknowledgment that the Americas trade situation makes growth 'difficult to predict' is more defensive than typical for a company reporting 14% organic growth."